Similar to the finding indicating that a modified version of tau (i.e., ultrasensitive blood immunoassay-detected tau phosphorylated at threonine 181) (70) appears to be a better marker of disease progression than t-tau, AβpE-related marker is a better biomarker of brain Aβ burden and cognitive decline than Aβ42 or t-tau, and may thus provide useful insights into brain functioning in the AD continuum. The gene discussed is MAPT; the disease is Alzheimer disease.